-
Senator Calls Out Bill Ackman, Questions His Senate Hearing Comments On Drug Pricing
Friday, April 29, 2016 - 12:48pm | 352Read More...Senator Susan Collins (R-Maine) was a guest on Bloomberg Markets to discuss Valeant Pharmaceuticals Intl Inc (NYSE: VRX) senate hearings into its drug pricing policies. The Bloomberg hosts pointed out that Bill Ackman, a major Valeant shareholder and board member, has an impressive track record...
-
Valeant's 10k Finally Released
Friday, April 29, 2016 - 8:39am | 248Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading lower by nearly 2 percent early morning after the company released its delayed 10-k filing which includes its first quarter results. Valeant reported it lost $1.12 per share in the first quarter on revenue of $2.76 billion....
-
WSJ: Valeant To Oversee 'Sweeping Changes' To Its Board Of Directors
Thursday, April 28, 2016 - 8:53am | 263Read More...The Wall Street Journal reported Wednesday evening that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is set to implement "sweeping changes" to its board of directors. The Wall Street Journal, citing "people familiar with the matter," stated that five of Valeant's long-standing directors have...
-
Bill Ackman Is The 'Unofficial Leader Of A Thundering Herd' That Lost Billions Of Dollars
Thursday, April 28, 2016 - 8:26am | 259Read More...Billionaire activist investor Bill Ackman has lost billions of dollars through his fund's large stake in Valeant Pharmaceuticals Intl Inc (NYSE: VRX) following the stock's nearly 85 percent collapse over the past year. Ackman also holds a seat at Valeant's board of directors and testified in front...
-
Wells Fargo's Analyst Discusses Valeant's 'Apology Tour'
Wednesday, April 27, 2016 - 2:58pm | 346Read More...David Maris is an analyst at Wells Fargo that initiated coverage of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) with a Sell rating back in February. On Wednesday, he was a guest on CNBC's Halftime Report segment to discuss his views on the company. Maris began by saying that appointing Joe Pappa...
-
Valeant Says Delayed 10-K Resulted In Several Notices Of Defaults
Monday, April 25, 2016 - 10:29am | 184Read More...Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced on Friday it has received several notices of defaults from trustees as a the result of its delayed 10-K filing. Valeant continued that the notices of default governing its 5.375 percent Senior Notes due 2020; 6.375 percent Senior...
-
Report: Valeant More Likely To Sell Drugs Than Business Units
Tuesday, April 19, 2016 - 10:25am | 251Read More...Faced with $30 billion in debt, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has few options at its disposal. Among the company's options to reduce its debt load includes selling off some of its drug assets, or selling complete business units. According to a report by Reuters, Valeant is...
-
Report: Valeant Has Tapped Investment Bankers To Help Review Strategic Options
Friday, April 15, 2016 - 11:55am | 189Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has hired investment bankers to explore its strategic options, according to Reuters. Reuters, citing "people familiar with the matter," reported that Valeant has tapped bankers and advisors at Goldman Sachs and Centerview Partners Holdings...
-
Goldman On Valeant: New Tax Inversion Rules Could Have 'Some' Impact, But Nothing Too Drastic
Tuesday, April 5, 2016 - 5:17pm | 409Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares had a strong Tuesday, up 10 percent, after the company's Ad Hoc Committee said it did not identify any additional items beyond the required restatements previously disclosed. "We see the conclusion of the Ad Hoc Committee review as...
-
VRX Memo: Addyi's Third-Party Sales Force To Be Cut When Contract Ends April 15, Planning Sales Effort Re-Launch
Tuesday, April 5, 2016 - 8:30am | 167Read More...Reuters reported after Monday's market close that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plans on cutting its sales force for Addyi, a treatment aimed at female sexual dysfunction. Reuters noted that an outside sales force handles sales for Addyi, which fell under Valeant's corporate...
-
Some Valeant Creditors Reportedly 'Balking' At Revised Lending Agreement; Investors Concerned
Monday, April 4, 2016 - 5:07pm | 223Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares finished a down Monday with a sharp move to the $26 mark after a Bloomberg report said the company's creditors were resistant to relaxed lending standards. According to a source with knowledge of the matter, Bloomberg said Valeant was...
-
Valeant In Breach Of Canadian Regulations
Thursday, March 31, 2016 - 12:20pm | 224Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) hit a new 52-week low of $25.75 on Thursday after Canadian authorities said the company is in breach of regulations. Valeant Pharmaceuticals is based in Laval, Quebec. The provincial regulator, the Autorite Des Marches Financiers, issued...
-
Why Valeant's New CEO Could Be An Allergan Exec
Monday, March 21, 2016 - 3:41pm | 601Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is trending amid the company's report it plans to move on from current CEO Mike Pearson. On Monday afternoon, analysts Shibani Malhotra and Austin Nelson at Nomura shared their short list of who would make sense to replace him. "In our view...
-
BMO Valeant Reaction: 10-K Could Give Investors Confidence To Value Shares Above $60
Monday, March 21, 2016 - 3:20pm | 247Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are selling off on Monday afternoon, following a higher morning amid news that the company will move on from its current CEO. The stock is still up 6 percent on the day. While Wall Street's reaction is mixed, one analyst is giving his...
-
Valeant And German Rockers 'The Scorpions' Have This In Common (And It's Not Good)
Monday, March 21, 2016 - 3:02pm | 503Read More...After the news broke it would part ways with CEO Mike Pearson amid new comments the company was concerned about its accounting and internal controls, one analyst at Canaccord Genuity is comparing Valeant Pharmaceuticals Intl Inc (NYSE: VRX) to German rock band "The Scorpions" in a note...
